STOCK TITAN

Cara Therapeutic - CARA STOCK NEWS

Welcome to our dedicated page for Cara Therapeutic news (Ticker: CARA), a resource for investors and traders seeking the latest updates and insights on Cara Therapeutic stock.

Overview

Cara Therapeutics is a biotechnology company dedicated to the development of novel therapeutics for the treatment of pain, inflammation, and pruritus. The company leverages advanced drug screening technology to build a pipeline of first‐in‐class molecules designed to address significant unmet medical needs. As an emerging biopharmaceutical firm, Cara Therapeutics has positioned itself within the clinical development arena through its innovative approach to drug discovery and targeted therapeutic interventions.

Core Therapeutic Focus

The company’s primary focus is on conditions that cause severe discomfort and impede quality of life, namely acute pain, inflammatory conditions, and pruritic disorders. Its lead compound, which exhibits analgesic, anti-inflammatory, and antipruritic properties, is under rigorous clinical exploration for multiple therapeutic applications. Cara Therapeutics actively pursues options to widen the therapeutic scope of its novel candidates, ensuring that each development program is rooted in robust scientific research and clinical validation.

Clinical Programs and Research

Cara Therapeutics’ clinical development efforts emphasize precision and innovation. The company’s most advanced therapy candidate currently undergoes clinical testing, reflecting its commitment to bridging the gap between scientific discovery and therapeutic application. The clinical programs are structured to assess not only the efficacy of these novel compounds but also their safety profile across clearly defined patient populations. This dedication to high-quality research underscores the company's broader mission of transforming treatment landscapes for complex conditions.

Innovative Drug Screening Technology

At the heart of Cara Therapeutics’ strategy is its proprietary drug screening platform which enables the discovery of unique molecules with potential analgesic and anti-inflammatory effects. This technology facilitates the rapid identification and development of candidates that might otherwise be overlooked in traditional screening methods, thereby enhancing the company’s ability to generate a sustainable pipeline of innovative treatments.

Market Position and Competitive Landscape

Operating in the highly competitive biotechnology industry, Cara Therapeutics distinguishes itself through its targeted approach to addressing conditions with significant therapeutic challenges. The company navigates a competitive field by aligning its development programs with specific unmet needs in the clinical treatment of pain and pruritus. By combining novel molecule development with a strategic focus on clinical validation, Cara Therapeutics ensures its place among specialized players in the biopharmaceutical market.

Business Model and Operational Strategy

The operational strategy of Cara Therapeutics is built on academic rigor and innovative clinical research. The company cultivates scientific expertise and leverages strategic partnerships to optimize its research and development processes. Revenue generation is expected to come from milestone achievements in clinical testing, licensing opportunities, and potential collaborations that support further drug development initiatives. This model reflects a balanced approach; it prioritizes strong foundational research while remaining responsive to emerging clinical insights.

Expertise and Industry Impact

The comprehensive approach taken by Cara Therapeutics highlights a deep understanding of the complex interplay between drug discovery, clinical validation, and regulatory considerations. The company’s methodical research and its investment in innovative screening technologies position it as an expert in the development of therapies for conditions marked by pain and pruritus. By addressing core patient needs with scientifically sound methodologies, Cara Therapeutics builds authority and trust within the clinical and investor communities.

Key Takeaways

  • Focused Therapeutic Targets: Specialized in pain, inflammation, and pruritus with a clear emphasis on patient-centric treatments.
  • Innovative R&D: Utilizes proprietary drug screening technology to develop a pipeline of novel molecules.
  • Clinical Depth: Engages in advanced clinical trials to evaluate the efficacy and safety of its lead compounds.
  • Market Differentiation: Strategically positioned in a competitive biotechnology landscape by aligning research with unmet medical needs.

This comprehensive overview of Cara Therapeutics is designed to provide investors and industry observers with a clear understanding of its operational framework, clinical ambitions, and overall healthcare significance. The company’s continued commitment to innovative drug development underlines its role in shaping future therapeutic paradigms, offering an in-depth look into its integrated approach spanning research, development, and clinical validation.

Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA), a biopharmaceutical company focused on treatments for pruritus, announced that CEO Christopher Posner will present at two investor conferences in May 2022. The first event is the BofA Securities 2022 Healthcare Conference on May 10 at 2 p.m. PT / 5 p.m. ET, followed by the H.C. Wainwright Global Investment Conference on May 25 at 2:30 p.m. ET. Webcasts of the presentations will be available on the company's website for 30 days. Cara is known for its FDA-approved KORSUVA™ (difelikefalin) injection for treating pruritus in chronic kidney disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences
-
Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) will hold a conference call on May 9, 2022, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a corporate update. The company is known for its KORSUVA™ injection, the sole FDA-approved treatment for moderate-to-severe pruritus linked to chronic kidney disease in adults undergoing hemodialysis. Cara is also developing an oral version of difelikefalin and has initiated Phase 3 programs targeting pruritus in patients with chronic kidney disease and atopic dermatitis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.88%
Tags
-
Rhea-AI Summary

On April 28, 2022, the European Commission granted marketing authorization for Kapruvia® (difelikefalin), the first therapy in Europe for treating chronic kidney disease (CKD)-associated pruritus in adult hemodialysis patients. This approval follows the FDA approval of KORSUVA™ in August 2021. The first launches in Europe are expected in the second half of 2022, addressing a significant unmet medical need. The authorization is based on pivotal data from two phase-III trials showing significant improvements in pruritus severity and quality of life for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
none
Rhea-AI Summary

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma announced that the European Commission has granted marketing authorization for Kapruvia® (difelikefalin). This is the first approved therapy for chronic kidney disease-associated pruritus in hemodialysis patients across Europe. Following FDA approval in August 2021, Kapruvia® is set to launch in the second half of 2022. Clinical data from phase-III trials demonstrated significant reductions in pruritus severity and improved quality of life for patients. The drug addresses a substantial unmet need in CKD management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.25%
Tags
none
-
Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced participation by CEO Christopher Posner in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 1:30 p.m. ET. Attendees can access the event via the company’s website under 'Events & Presentations,' with an archived recording available for 30 days post-event. Cara is recognized for its FDA-approved KORSUVA™ (difelikefalin) injection, the first treatment for moderate-to-severe pruritus in chronic kidney disease patients undergoing hemodialysis. The company is advancing additional formulations and ongoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
conferences
-
Rhea-AI Summary

Cara Therapeutics (Nasdaq: CARA) announced the presentation of biomarker data from the KALM-1 and KALM-2 clinical trials for KORSUVA (difelikefalin) at the National Kidney Foundation Spring Clinical Meetings 2022. The poster highlights a reduction in itch intensity correlated with decreased inflammatory markers in patients with chronic kidney disease-associated pruritus undergoing hemodialysis. Presentations will take place on April 7, 2022, with additional posters addressing treatment effects on itch severity and sleep disruption. KORSUVA is the first FDA-approved treatment for this condition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
Rhea-AI Summary

Cara Therapeutics, Inc. (Nasdaq: CARA) presented late-breaking data at the 2022 AAD Annual Meeting, highlighting the effectiveness of Oral KORSUVA™ (difelikefalin) in treating pruritus and inflammation in patients with moderate-to-severe atopic dermatitis. The KARE Phase 2 trial sub-study involved 40 patients, revealing significant downregulation of pruritus-related genes after 12 weeks of treatment. This indicates difelikefalin's potential as a dual-action therapy, addressing both itch and inflammation. Quality of life improvements were also noted, enhancing the overall treatment landscape for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Cara Therapeutics (NASDAQ: CARA) announced that biomarker data from the KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for treating moderate-to-severe pruritus in atopic dermatitis will be presented at the 2022 AAD Annual Meeting on March 26, 2022. The company will also host a virtual R&D event on March 11, 2022, to discuss Phase 3 programs for pruritus in advanced chronic kidney disease and atopic dermatitis. The KORSUVA injection is the first FDA-approved treatment for chronic kidney disease-related pruritus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.17%
Tags
none
-
Rhea-AI Summary

Cara Therapeutics reported financial results for Q4 and full-year 2021, highlighting a significant drop in revenue to $0.8 million from $112.1 million year-over-year. The net loss for Q4 was $33.4 million, or $(0.63) per share, compared to a profit in the prior year.

The company is preparing for the U.S. launch of KORSUVA injection in April 2022 and has initiated Phase 3 trials for Oral KORSUVA in chronic kidney disease and atopic dermatitis. Cara's cash reserves stand at $236.8 million, sufficient for operations through 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.61%
Tags
Rhea-AI Summary

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Kapruvia® (difelikefalin) for treating chronic kidney disease-associated pruritus in hemodialysis patients. This therapy would be the first of its kind in Europe. The European Commission's decision on marketing authorization is anticipated in Q2 2022. Meanwhile, Kapruvia® is already approved in the US as KORSUVA™. The positive recommendation is based on pivotal phase-III trials showing clinically meaningful improvements in symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
none

FAQ

What is the current stock price of Cara Therapeutic (CARA)?

The current stock price of Cara Therapeutic (CARA) is $4.95 as of April 3, 2025.

What is the market cap of Cara Therapeutic (CARA)?

The market cap of Cara Therapeutic (CARA) is approximately 23.2M.

What is the primary focus of Cara Therapeutics?

Cara Therapeutics specializes in developing novel therapeutics to treat conditions associated with pain, inflammation, and pruritus. The company focuses on creating therapies that address significant unmet medical needs.

Can you explain the significance of the company’s lead compound?

The lead compound under clinical evaluation exhibits analgesic, anti-inflammatory, and antipruritic properties, targeting acute pain and pruritic disorders. It represents the company’s commitment to delivering first-in-class therapeutic options.

How does Cara Therapeutics develop its drug pipeline?

Cara Therapeutics employs proprietary drug screening technology to identify and develop unique molecules with therapeutic potential. This approach enables the company to build a sustainable pipeline of novel candidates.

What therapeutic areas does the company address?

The company focuses on therapeutic areas involving pain management, inflammation, and pruritus. Its research targets conditions where traditional treatments may not adequately address patient needs.

How is the company positioned within the biotech industry?

Cara Therapeutics is positioned as a clinical-stage biotechnology firm that differentiates itself through innovative research and focused therapeutic development. Its strategy centers on addressing critical unmet needs in its target markets.

How does the proprietary drug screening technology benefit Cara Therapeutics?

The proprietary technology enhances the efficiency and accuracy of identifying novel therapeutic candidates. This innovative approach not only accelerates development timelines but also expands the potential for groundbreaking treatments.

What are the main factors that compromise the competitive landscape for the company?

Operating in a competitive space, Cara Therapeutics differentiates itself through focused research and technological innovation. While many companies aim to address similar conditions, its unique approach and clinical strategies set it apart.
Cara Therapeutic

Nasdaq:CARA

CARA Rankings

CARA Stock Data

23.23M
3.96M
13.18%
24.52%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
STAMFORD